Kidney Disease Outcomes Quality Initiative (K/DOQI) guidelines suggest that angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) are preferred because they may provide greater benefits, such as relatively more left ventricular hypertrophy regression